(Z)-tert-Butyl 4-(N'-hydroxycarbamimidoyl)piperidine-1-carboxylate

Catalog No. :
ACITKC172
CAS No. :
782493-60-1
Molecular Formula :
C11H21N3O3
Molecular Weight :
243.31

IUPAC Name:tert-butyl 4-(N-hydroxycarbamimidoyl)piperidine-1-carboxylate

(Z)-tert-Butyl 4-(N'-hydroxycarbamimidoyl)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$260.00Login to see priceIn stockInquiry
5g95%$842.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(Z)-tert-Butyl 4-(N'-hydroxycarbamimidoyl)piperidine-1-carboxylate
IUPAC Nametert-butyl 4-(N-hydroxycarbamimidoyl)piperidine-1-carboxylate
MDL No.MFCD09951950
Molecular FormulaC11H21N3O3
Molecular Weight243.31
SMILESO=C(N1CCC(/C(N)=N/O)CC1)OC(C)(C)C
InChI KeyKMBRLTGPGNMNIY-UHFFFAOYSA-N
Synonym1-PIPERIDINECARBOXYLIC ACID, 4-[(Z)-AMINO(HYDROXYIMINO)METHYL]-, 1,1-DIMETHYLETHYL ESTER;Tert-Butyl 4-[(Z)-Amino(Hydroxyimino)Methyl]Piperidine-1-Carboxylate(WX690178);tert-Butyl (Z)-4-(N'-hydroxycarbamimidoyl)piperidine-1-carboxylate
CAS No.782493-60-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACITKC172 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACITKC172 route product structure diagram
    ACITKC172782493-60-1 In Stock
Inquiry

2. ACITKC172 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACITKC172 route product structure diagram
    ACITKC172782493-60-1 In Stock
Inquiry

Comments (0)